A model for the future conduct of pharmacovigilance
Top Cited Papers
- 1 November 2002
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 12 (1) , 17-29
- https://doi.org/10.1002/pds.773
Abstract
A scientific model to support excellence in pharmacovigilance has been developed from first principles by brainstorming sessions and discussions with experts in the field. The model represents a long‐term vision of how pharmacovigilance could be conducted in the future. So far it has been developed without any consideration of constraints such as resources or the need for legislative change. Although the vision is holistic, it would be possible to test and implement parts of the model in a piecemeal fashion. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 10 references indexed in Scilit:
- Modeling methods for facilitating decisions in pharmaceutical policy and population therapeuticsPharmacoepidemiology and Drug Safety, 2002
- Monitoring the safety of over the counter drugsBMJ, 2001
- What Will Be the Role of Pharmacogenetics in Evaluating Drug Safety and Minimising Adverse Effects?Drug Safety, 2001
- Responding to drug safety issuesPharmacoepidemiology and Drug Safety, 1999
- Prescription‐event monitoring—recent progress and future horizonsBritish Journal of Clinical Pharmacology, 1998
- Getting research findings into practice: Decision analysis and the implementation of research findingsBMJ, 1998
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998
- The Role of the WHO Programme on International Drug Monitoring in Coordinating Worldwide Drug Safety EffortsDrug Safety, 1998
- Regulatory Pharmacovigilance in theUnitedKingdom: Current Principles and PracticePharmacoepidemiology and Drug Safety, 1996
- David Byar as a teacherControlled Clinical Trials, 1995